Strategic customers Secure and scalable contracts with large government and veteran care programs, leveraging recent VA and DoD partnerships and FDA-cleared Hemastyl to expand adoption and case volumes among military and veteran healthcare networks.

Clinical differentiation Position Hemastyl as a unique solution for neuropathy-related wound healing with rapid closure rates, targeting hospital systems and wound care centers facing high amputation rates and chronic wounds, to drive faster adoption and comprehensive peri-wound care programs.

Expansion readiness Capitalize on upcoming commercial deployment starting May 2026 to upsell into IDNs and regional health networks, aligning supply contracts with procurement cycles and formulary approvals to maximize year-over-year revenue growth.

Strategic partnerships Leverage relationships with VA and DoD to explore expanded pilots, training programs, and data-sharing collaborations that demonstrate real-world outcomes, aiding reimbursement discussions and broader market access.

Financial runway Highlight the combination of FDA clearance, a multi-million revenue runway, and existing funding to de-risk enterprise deals, while targeting tiered contracts and long-term service agreements to stabilize cash flow and expand customer lifetime value.